Premium
Vigam‐S, a solvent/detergent‐treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura
Author(s) -
Newland A. C.,
Burton I.,
Cavenagh J. D.,
Copplestone A.,
Dolan G.,
Houghton J.,
Reilly T.
Publication year - 2001
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1046/j.1365-3148.2001.00281.x
Subject(s) - medicine , platelet , thrombocytopenic purpura , aseptic meningitis , vomiting , gastroenterology , adverse effect , seroconversion , anesthesia , antibody , surgery , immunology , cerebrospinal fluid
. The efficacy of Vigam‐S, a highly purified intravenous immunoglobulin, was investigated by an open, noncomparative study in 20 adults with chronic idiopathic thrombocytopenic purpura (ITP). Fifteen patients responded to the initial 3‐day infusion of 0·4 g kg −1 day −1 by exhibiting an incremental increase in platelet count of ≥ 30 × 10 9 L −1 , in eight of whom platelet count normalized (> 150 × 10 9 L −1 ). The peak platelet count for responders on day 4 was 163 × 10 9 L −1 (baseline = 18 × 10 9 L −1 ). No benefit was derived from an extra 2 days infusion in nonresponders. Further treatment (either a single 0·8 g kg −1 dose or another 3‐day infusion) given to responders when platelet counts fell below 30 × 10 9 L −1 was effective on eight of 14 occasions. Increases in total serum IgG concentration (to a mean peak of 25·3 g L −1 ) were not correlated with platelet response. There was no evidence of seroconversion to virus markers, or of alteration in renal function, following Vigam‐S infusion. Most adverse events were mild and transient; however, three patients had severe headache and vomiting (possible aseptic meningitis syndrome) and one had marked superficial thrombophlebitis. Therefore Vigam‐S provides effective and well tolerated therapy in the management of adults with ITP although individual patient response remains difficult to predict.